Interv Akut Kardiol. 2008;7(4):143-146

The role of catheter ablation in prevention of thromboembolic stroke

Martin Fiala
Kardiocentrum Nemocnice Podlesí, Třinec

Atrial fibrillaton (AF) is associated with increased risk of thromboembolic stroke. Clinical course of the ischemic stroke in patients with AF is worse compared to that in patients without AF. Anticoagulation represents the current basis of stroke prevention in patients with AF, although it includes many drawbacks and does not reduce the incidence of stroke to the level of population without AF. Permanent sinus rhythm offers the best prevention of thromboembolic stroke; however, effectiveness of the antiarrhythmic drugs to achieve this goal is low. Catheter ablation is much more potent in long-term elimination of AF compared to antiarrhythmic drugs; however, we are still lacking data from prospective randomized studies showing how this fact projects into the reduction of thromboembolic complications. Yet, results of studies encompassing large numbers of patients demonstrate that successful ablation is associated with significant reduction of thromboembolic complications, and that after successful ablation and discontinuation of warfarin, the incidence of tromboembolic events returns to the level of population without AF.

Keywords: atrial fibrillation, thromboembolic stroke, catheter ablation

Published: December 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fiala M. The role of catheter ablation in prevention of thromboembolic stroke. Interv Akut Kardiol. 2008;7(4):143-146.
Download citation

References

  1. Wolf PA, Benjamin EJ, Belanger AJ, et al. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J 1996; 131: 790-795. Go to original source... Go to PubMed...
  2. Furberg CD, Psaty BM, Manolio TA, et al. CHS Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241. Go to original source... Go to PubMed...
  3. Manolio TA, Furberg CD, Rautaharju PM, et al. Cardiac arrhythmias on 24 hour ambulatory electrocardiography in older women and men: The Cardiovascular Health Study. J Am Coll Cardiol 1994; 23: 916-924. Go to original source... Go to PubMed...
  4. Tsang TS, Petty GW, Barnes ME, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003; 42: 93-100. Go to original source... Go to PubMed...
  5. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projection for future prevalence. Circulation 2006; 114: 119-125. Go to original source... Go to PubMed...
  6. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998; 158: 229-234. Go to original source... Go to PubMed...
  7. Benjamin EJ, Wolf PA, D´Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952. Go to original source... Go to PubMed...
  8. Dries DL, Aarons D, Exner DV, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction. A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32: 695-703. Go to original source... Go to PubMed...
  9. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigators of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001; 104: 292-296. Go to original source... Go to PubMed...
  10. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-179. Go to original source... Go to PubMed...
  11. The Boston area anticoagulation trial for atrial fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
  12. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. Final results. Circulation 1991; 84: 527-539. Go to original source... Go to PubMed...
  13. Stroke prevention in atrial fibrillation investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84: 527-539.
  14. Ezekowitz M, Bridgers S, James K, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327; 1406-1412. Go to original source... Go to PubMed...
  15. Roy D, Takajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920. Go to original source... Go to PubMed...
  16. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl. J Med 2005; 352: 1861-1872. Go to original source... Go to PubMed...
  17. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42: 185-197. Go to original source... Go to PubMed...
  18. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. The APAF study. J Am Coll Cardiol 2006; 48: 2340-2347. Go to original source... Go to PubMed...
  19. Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27: 216-221. Go to original source... Go to PubMed...
  20. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293: 2634-2640. Go to original source... Go to PubMed...
  21. Wolf PA, Dawber TR, Thomas HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke. The Framingham Study. Neurology 1978; 28: 973-977. Go to original source... Go to PubMed...
  22. Wolf PA, Abbot RD, Kannel WB, et al. Atrial fibrillation as independent risk factor for stroke: The Framingham study. Stroke 1991; 22: 983-988. Go to original source... Go to PubMed...
  23. Lamasa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001; 32: 392-398. Go to original source... Go to PubMed...
  24. Gustafsson C, Britton M. Pathogenetic mechanism of stroke in non-valvular atrial fibrillation: follow-up of stroke patients with and without atrial fibrillation. J Intern Med 1991; 230: 11-16. Go to original source... Go to PubMed...
  25. Sandercock P, Bamford J, Dennis M, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). BMJ 1992; 305: 1460-1465. Go to original source... Go to PubMed...
  26. Duli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003; 22: 118-123. Go to original source... Go to PubMed...
  27. Miyasaka Y, Barnes ME, Gersh BJ, et al. Time trend of ischemic stroke and mortality incidence in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke 2005; 36: 2362-2366. Go to original source... Go to PubMed...
  28. Lakshminarayan K, Solid CS, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002). Stroke 2006; 37: 1969-1974. Go to original source... Go to PubMed...
  29. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262. Go to original source...
  30. Andersen KK, Olsen TS. Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22 179 patients with ischemic stroke. Stroke 2007; 38: 259-263. Go to original source... Go to PubMed...
  31. Somerfield J, Barber PA, Anderson NE, et al. Not all patients with atrial fibrillation-associated stroke can be started on anticoagulant therapy. Stroke 2006; 37: 1217-1220. Go to original source... Go to PubMed...
  32. The AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109; 1509-1513. Go to original source... Go to PubMed...
  33. Ouyang F, Bänsch D, Ernst S, et al. Complete isolation of the left atrium surrounding the pulmonary veins: new insights from the double-lasso technique in paroxysmal atrial fibrillation. Circulation 2004, 110 (15), 2090-2096. Go to original source... Go to PubMed...
  34. Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 2004; 109: 327-334. Go to original source... Go to PubMed...
  35. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111: 1100-1105. Go to original source... Go to PubMed...
  36. Oral H, Chugh A, Özaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006; 114: 759-765. Go to original source... Go to PubMed...
  37. The Atrial Fibrillation Follow up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.